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Objective: To examine the association between the current use of analgesics and the risk of falls in people with
knee osteoarthritis (KOA).
Methods: A retrospective cohort study using data from the UK Clinical Practice Research Datalink, with linkage to
Hospital Episode Statistics data. People diagnosed with KOA in England between 2000 and 2014 were included.
The studied analgesic classes were antidepressants, antiepileptic drugs (AEDs), opioids, non-steroidal anti-in-
flammatory drugs (NSAIDs) and paracetamol. Cox Proportional Hazards model was used to estimate the risk of
fall with current use of analgesics within one year of KOA diagnosis, reported as Hazard Ratio (HR) with 95%
Confidence Intervals (CI).
Results: This study included 57,383 patients (mean age [SD] 67.0 [12.8] years, 59.3% were female); 44,010
(76.7%) were prescribed analgesics at least once within one year of KOA diagnosis. Within the first six months of
KOA diagnosis, the reported HR (95%CI) were 1.46 (1.20, 1.78), 1.40 (0.91, 2.16), 2.40 (2.01, 2.85), 1.72 (1.43,
2.07), 1.98 (1.68, 2.33), while between 6 and 12 months after KOA diagnosis, the HR (95%CI) were 2.68 (2.14,
3.36), 2.22 (1.70, 2.91), 1.96 (1.70, 2.26), 1.47 (1.21, 1.78), 1.92 (1.63, 2.26) for antidepressants, AEDs, opioids,
NSAIDs and paracetamol, respectively and adjusted for important potential confounders.
Conclusion: The current use of analgesics was associated with an increased risk of falls within one year of KOA
diagnosis. These findings identify people with KOA who use analgesics as a priority for fall prevention programs/
interventions, in an effort to optimise safety of analgesics in this population.1. Introduction
Osteoarthritis (OA) is the most common chronic progressive muscu-
loskeletal condition that affected 303million people globally in 2017 [1].
It can affect any joint, however, knees are most commonly involved with
18.2% of people aged over 45 years in England being affected by knee
osteoarthritis (KOA) and the prevalence increases with age [2]. It was
reported that OA of the knee accounts for 83% of the total OA burden [3].
Treatment focuses on relieving pain and improving joint function, as
currently, no curative therapy exists. Management includes prescribing
analgesics such as paracetamol, non-steroidal anti-inflammatory drugs
(NSAIDs) and opioids [4] or antidepressants [5]. Although noty, Sultan Qaboos University Hosp
m 31 March 2021; Accepted 6 A
ier Ltd on behalf of Osteoarthritisrecommended by many international guidelines, anti-epileptic drugs
(AEDs) are still prescribed for chronic non-cancer pain (CNCP) conditions
including OA, as an off-label use [6]. Antidepressants and AEDs are
centrally acting drug classes that are used in clinical practice for neuro-
pathic pain management [7]. The use of analgesics is common among
people with OA and ranges from 50% to 64% in community dwelling
patients with OA [8–10]. Moreover, evidence suggests that people with
OA have different patterns of analgesic use, including switching to an
alternative analgesic class, augmentation with another analgesic or
discontinuation of prescribed analgesics [8].
In common with older people, patients with OA might be at risk for
drug-related adverse events caused by age related physiological changes,ital, Pharmacy Department, PO Box 38 PC123, Muscat, Oman.
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patients with KOA are at a greater risk for certain adverse events such as
falls, due to joint instability and severe pain [12]. Falls are a major public
health concern in the UK and many countries around the world, partic-
ularly those with ageing populations [13]. Whilst the use of analgesics
particularly those with Central Nervous System (CNS) effects including
opioids and antidepressants, has been identified as a risk factor for falls
among older patients (aged 60 years) [14–17], this association is less
well described in patients with KOA.
Studies were limited with the inclusion of only two analgesic classes
[18], or the exposure was measured after establishment of long term
analgesic (opioids) use [19]. In another study, exposure data (pre-
scriptions taken in the previous month) collected at an annual interview
while the outcome event was self-reported [20]. Hence, it is unclear
whether fall risk varies during periods of analgesic use compared to pe-
riods of no-analgesic use in patients with KOA. Moreover, the relative
safety of analgesic classes in relation to risk of fall is understudied.
The present study aimed to examine the association between current
exposure to individual analgesic classes and the risk of fall for the
following classes – antidepressants, AEDs, opioids, NSAIDs and paracet-
amol – compared to no-current exposure.
2. Methods
2.1. Study design
This was a retrospective cohort study.
2.2. Data source
Data were obtained from the Clinical Practice Datalink (CPRD GOLD)
and linked Hospital Episode Statistics (HES). CPRD is a large primary
care database that contains records of patients from practices across the
UK since 1987 [21]. Data are collected as part of the normal clinical care
when patients consult their general practitioners GPs, in participating
practices. Within CPRD, therapy variables include drug name, strength,
product code, numeric daily dose (NDD) and quantity. As of July 2013,
674 practices contributed data to CPRD GOLD and records of more than
4.4 million active patients were included [22]. The HES database con-
tains information on all admissions to NHS trusts in England and data are
collected during a patient’s stay at hospital [23].
2.3. Study population
The study included adults with a recorded KOA diagnosis between
January 1, 2000 and December 31, 2014 and had a record in the CPRD
linked to HES data. Cases were defined using Read codes for KOA
(Supplementary materials). Read codes are a hierarchical clinical coding
system of over 80,000 terms that are used to record clinical data in
general practice in the UK [24]. Each patient’s study entry date was the
date of the first recorded diagnosis of KOA in CPRD (index diagnosis
date) until the earliest date of: first fall, death, transfer out (date the
patient transferred out of the practice) or end of follow-up period
(December 31, 2015). Patients were eligible for inclusion if their KOA
diagnosis occurred at least 12 months after registration with the GP
practice.
2.4. Exposure
Details of all analgesic prescriptions for the study cohort were ob-
tained from CPRD (therapy file) following their index diagnosis. Anal-
gesics were grouped into five exposure groups according to the
prescribed analgesic class including: antidepressants, AEDs, opioids,
NSAIDs and paracetamol (supplementary materials). The duration of
each prescription was calculated by dividing the total quantity prescribed
by the NDD, and the number of treatment episodes per patient for each2
analgesic class was then determined. A treatment episode (exposure
period) was defined as a period of continuous analgesic use without gaps
of more than 60 days between the end of a prescription (prescription’s
supply) and the start of the next prescription. A prescription after more
than 60 days was counted as the start of a new treatment episode. Within
general practice, prescriptions for an individual patient are generated at
regular intervals of about a month up to two months’ duration. This re-
flects a pattern of prescribing when a patient requires a repeat pre-
scription at regular intervals because they have used up their previous
supply of medication. A gap of >60 days would therefore, most likely
indicate a period on no-analgesic use [25].
2.5. Outcome
Information on the first recorded fall within one year of KOA diag-
nosis was extracted using Read and ICD-10 codes (supplementary ma-
terials). The period of 12 months after diagnosis was selected as the
majority of primary care patients with a diagnosis of KOA switch,
augment or discontinue their analgesic treatments 2–6 months after
initiation [8]. Hence a period of 12 months after KOA was selected to
incorporate more periods of treatment (analgesic use) and more events
(falls) than a shorter follow-up (e.g. 2- or 6-months), thus avoiding any
concerns over under-powering the study.
2.6. Potential confounding variables
Age at the index diagnosis, gender, patient-level deprivation score
(defined by the index of multiple deprivation [IMD] quintiles, a measure
of relative deprivation/disadvantage) [26,27], previous falls, comor-
bidities and the use of fall risk increasing drugs (FRIDs) were included
[28]. These were captured within 12 months prior to the index diagnosis
date and were treated as binary variables. Comorbidities included:
depression, seizure disorders, coronary heart disease (CHD), diabetes,
hypertension, stroke and chronic obstructive pulmonary disease (COPD)
and were identified using Read code lists available from the Quality and
Outcome Framework (QOF) business rules [29]. Additionally, the prior
use of other analgesic classes (other than the class analysed) at baseline
was captured.
2.7. Statistical analysis
Cox proportional hazards model was used to estimate the associations
between current use of analgesic drugs and the risk of falls, while treating
analgesic exposure as a time-varying exposure. Applying time-varying
analysis accounts for treatments changing during follow-up and chang-
ing from treatment to no treatment. Furthermore, such analysis addresses
the immortal time bias (ITB) that is potentially present in crude time-
fixed analysis. ITB occurs when there is variation in the timing of treat-
ment initiation from cohort entry and time to treatment is ignored [30].
The entry date in the analysis was the date of KOA diagnosis and the
date of the first fall after KOA diagnosis was marked as the event date.
The period of 12 months after the diagnosis of KOA was split into two 6-
month periods from the time of index KOA diagnosis (i.e., 0–6 months,
and from 6 to 12 months). This was done because there was some evi-
dence of non-proportional hazards over one, three and five years of
follow-up, seen as crossing log-log curves on at least one point. The split
of the follow-up period was also done to investigate changes in hazard
ratios over time since KOA diagnosis. Patients who did not experience
any fall were censored at the earliest date of: death, transfer out, study
end or the end of the first year of follow-up.
A separate Cox proportional-hazards regression model was applied
for each analgesic class. Assumptions for performing Cox models were
examined and were upheld. The analysis calculated Hazard Ratio (HR)
and 95% Confidence Intervals (CI) for the current use of each analgesic
class compared with no-current use. Statistical significance was reported
as Pvalues of <0.05% using Chi-squared test.
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gesic class) and this included periods of non-exposure in patients treated
with analgesics as well as periods of non-exposure from patients who
were not prescribed any analgesics over the follow-up period.
CPRD data files were downloaded in a zipped text format from the
CPRD Gold interface, while HES data were provided by the CPRD staff.
Data cleaning involved data inspection for missing information or out-
liers. Patient records with missing year of birth (yob) were excluded.
Incomplete prescription data for prescribed quantity were excluded
(n ¼ 150, 0.03% of total prescriptions). Prescriptions with missing NDD
were imputed with doses published in the British National Formulary
[31], while outliers included non-plausible values of NDD (i.e. values 
10 times the maximum) and were treated as missing data (total pre-
scriptions with missing NDD ranged between 8% (n ¼ 2134) and 27% (n
¼ 47,736), for AEDs and opioids respectively).
Analyses were carried out using Stata 15.1 (StataCorp. 2017). ThisTable 1
Characteristics of the study population.





Mean (SD) 67.04 (12.82)
Range (18.03–104.72)





IMD score (% from total)




5 (most deprived) 8620 (15.0%)
a Age at KOA diagnosis IMD: index of multiple deprivation.
Table 2
Characteristics of study cohort (n ¼ 57,383) stratified by drug class. values are numb
Antidepressant AED
n ¼ 11,569 n ¼ 2635
Females (%) 8488 (73.3) 1704 (64.6)
Mean age, years (SD) 67.0 (13.6) 65.8 (12.9)
Age groupsa, years (% from total prescribed respective drug class)
>40 239 (2.1) 41 (1.6)
40–64 5228 (45.2) 1175 (44.6)
65–80 4113 (35.5) 1015 (38.5)
>80 1989 (17.2) 404 (15.3)
IMDs score
1(least deprived) 2099 (18.1) 428 (16.2)
2 2472 (21.4) 576 (21.9)
3 2411 (20.8) 515 (19.5)
4 2402 (20.8) 558 (21.2)
5 2177 (18.8) 556 (21.1)
Not recorded 8 (0.1) 2 (0.1)
Comorbidities at baseline
Cardiovascular disease 930 (8.0) 179 (6.8)
Diabetes 463 (4.0) 106 (4.0)
COPD 262 (2.3) 67 (2.5)
Epilepsy 115 (1.0) 443 (16.8)
Stroke 124 (1.1) 44 (1.7)
Depression 1790 (15.4) 187 (7.1)
Other characteristics at baseline
Using FRID 7812 (67.5) 1883 (71.5)
Using analgesicsb 9948 (86.0) 2402 (91.2)
Previous fall 1432 (12.4) 379 (14.4)
a Age at KOA diagnosis.
b Analgesics other than the studied class FRID: fall risk increasing drugs; IMD: inde
inflammatory drugs; COPD: Chronic Obstructive Pulmonary Disease; SD: standard de
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research was approved by the Independent Scientific Advisory Commit-
tee (ISAC) (protocol number 18_170R).
3. Results
This study included 57,383 patients diagnosed with KOA between
January 2000 and December 2014 and had HES-linked records
(Figure S1 supplementary materials); 44,010 (76.7%) were prescribed
analgesics at least once within one year of KOA diagnosis and 13,373
(23.3%) were not prescribed any. The sociodemographic and clinical
characteristics of the study population are summarised in Tables 1 and 2.
Across the studied analgesic classes, the majority of users were females
(between 60.0% and 73.3%). The mean age of paracetamol users was
higher compared to users of the other analgesic classes (Table 2). In total,
465,536 analgesic prescriptions were prescribed within the first year of
KOA diagnosis (Table 3).
3.1. Number and proportion of patients who experienced a fall
A total 2384 patients experienced a fall within one year of KOA
diagnosis, (4.1% of the study population N ¼ 57,383) (Table 4). Among
them, nine patients had a fall on the day of index diagnosis of KOA and
were excluded in further analyses, leaving a total of 57,374 patients, and
2375 of them experienced a fall.
3.2. Association between analgesic use and the risk of falls
The unadjusted and adjusted HRs (95% CI) showed a significant as-
sociation between analgesic use and the risk of falls for all analgesic
classes and over both six-month follow-up periods, apart from AEDs in
0–6 months (Table 5). The log rank test was used to test the equality of
survivor function for both intervals (0–6 and 6–12 months of KOA
diagnosis) and P value were statistically significant for all classes (P<
0.001).
Across analgesic classes within 6 months of KOA diagnosis, the cur-
rent use of opioids was associated with the greatest risk of fall versus noers of patients (%) unless stated otherwise.
Opioids NSAIDs Paracetamol
n ¼ 26,997 n ¼ 20, 473 n ¼ 16,007
17,227 (63.8) 12,297(60.0) 10,635 (66.4)
68.2 (12.5) 66.6 (11.6) 73.8 (11.6)
342 (1.3) 398(1.9) 105(0.7)
10,542(39.0) 9372(45.8) 3797(23.7)
11,317(41.9) 8201 (40.1) 7481(46.7)
4796 (17.8) 2511(12.2) 4624(28.9)
4836 (17.9) 4124 (20.1) 2767 (17.3)
5962 (22.1) 4666 (22.8) 3582 (22.4)
5523 (20.5) 4428 (21.6) 3498 (21.8)
5613 (20.8) 3997 (19.5) 3331 (20.8)
5050 (18.7) 3249 (15.9) 2825 (17.6)
13 (0.05) 9 (0.1) 4 (0.1)
2286 (8.5) 1464 (7.1) 1508 (9.4)
1074 (3.9) 649 (3.1) 692 (4.3)
529 (1.9) 228 (1.1) 307 (1.9)
252 (0.9) 160 (0.7) 191 (1.1)
212 (0.7) 100 (0.4) 171 (1.0)
1424 (5.2) 965 (4.7) 752 (4.6)
17,712 (65.6) 11,306 (55.2) 11,300 (70.5)
19,417 (71.9) 14,532 (70.9) 12,471(77.9)
2790 (10.3) 1392 (6.7) 2020 (12.6)
x of multiple deprivation; AEDs: Antiepileptic drugs; NSAIDs: non-steroidal anti-
viation.
Table 3














Antidepressants 11,569 20.1 97,545 21.0
AEDs 2635 4.5 26,687 5.7
Opioids 26,997 47.0 176,802 38.0
NSAIDs 20,473 35.6 82,347 17.7
Paracetamol 16,007 27.8 82,155 17.6
AEDs: Antiepileptic drugs NSAIDs: non-steroidal anti-inflammatory drugs
*exceeds 100% as some patients were prescribed > 1 class.
Table 4
Number (%) of patients who experienced a falla.
Patients who
experienced a fall










250 (1.8%) 13,114 (98.2%) 13,364
(100%)
<0.001
a This is a crude analysis.
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use of paracetamol, NSAIDs and antidepressants (HR-adjusted [95%CI])
of (1.98 [1.68, 2.33], 1.72 [1.43, 2.07], 1.46 [1.20, 1.78] respectively)
(Table 5). An example of survival curves for current use versus no-use for
paracetamol are presented in supplementary materials.
Between 6 and 12 months after KOA diagnosis, the greatest risk of fall
was associated with the current use of antidepressants followed by AEDs
with HR-adjusted (95% CI) of 2.68 (2.14, 3.36) and 2.22 (1.70, 2.91)
respectively and was increased since first six months (Table 5). The as-
sociation between current opioid use and the risk of fall was attenuated in
the second 6-month period with HR-adjusted (95% CI) of 1.96 (1.70,
2.26), although remained statistically significant. Unlike opioids, NSAIDs
and paracetamol, for which the HRs lowered in the second follow-up
interval, the adjusted HRs for antidepressants and AEDs increased in
the second interval compared to the first one.
The proportional hazard assumption was tested using Schoenfeld
residuals and the Pvalue was found not significant (P¼ 0.38). This
implied that the proportional hazards assumption was not violated.Table 5
Association between analgesic use and the risk of fall.
Unadjusted
0–6 months
HR 95% CI P va
No current use 1.0 Reference Refe
Antidepressants 2.52 2.17–2.89 <0.0
AEDs 2.01 1.53–2.63 <0.0
Opioids 3.11 2.74–3.53 <0.0
NSAIDs 1.70 1.45–2.00 <0.0
Paracetamol 3.61 3.13–4.16 <0.0
6–12 months
No current use 1.0 Reference Refe
Antidepressants 2.31 1.98–2.69 <0.0
AEDs 2.02 1.55–1.65 <0.0
Opioids 2.58 2.26–2.94 <0.0
NSAIDs 1.51 1.27–1.79 <0.0
Paracetamol 3.32 2.88–3.84 <0.0
AEDs: Antiepileptic drugs; NSAIDs: non-steroidal anti-inflammatory drugs; HR: hazar




The current use of analgesic medicines was associated with an
increased risk of fall compared to periods of no use in people diagnosed
with KOA. The risk ranged from more than 2-fold higher in those
currently prescribed opioids, antidepressants, AEDs or paracetamol, and
up to 72% higher in those currently using NSAIDs during the first year of
KOA diagnosis. The risk of falls varied across follow-up intervals and
showed a stronger association with the current use of opioids, NSAIDs
and paracetamol in the first 6 months after KAO diagnosis. On the other
hand, the current use of antidepressants and AEDs showed a stronger
association with the risk of fall within 6–12 months after KOA diagnosis.
4.2. Comparison with other studies
The present study’s findings were in agreement with those reported in
a case-control study in UK primary care using data from The Health
Improvement Network (THIN) database [17]. The study found that there
was an increased risk of fall with the current prescribing of serotonin
norepinephrine reuptake inhibitor antidepressants (SNRIs) (adjusted OR
[95% CI] of 1.79 [1.42, 2.25]) compared to controls [17]. Similarly, a
population-based cohort study using UK primary care data reported an
increased risk of fall with current antidepressant use [16]. The reported
HRs (95% CI) were 1.66 (1.58, 1.73) for SSRIs, 1.39 (1.28, 1.52) for other
antidepressants and 1.30 (1.23, 1.38) for tricyclic antidepressants.
Although both studies included patients aged 60 years or older who were
diagnosed with depression, the estimated risks may be different in people
with painful conditions such as KOA. The risk in the second 6-month
interval within the present study was higher than that reported by
Coupland et al. (2011). This could be explained by the shorter follow-up
period compared to a follow-up of 5 years in Coupland et al.’s study,
resulting in a smaller number of treatment and non-treatment periods,
potentially leading to an over-estimation of the association.
The present study also found an association between current use of
AEDs and the risk of falls within 6–12 months after KOA diagnosis. This
was in agreement with findings of a recent study using the US Renal Data
System [32]. The current use of gabapentin and pregabalin was associ-
ated with a significant increase in the risk of fall with HR (95%CI) of 1.35
(1.15, 1.57) and 1.68 (1.36, 2.08), respectively.
Consistent with previous research findings, this study found an as-
sociation between current opioid use and the risk of fall. In a study of
community-dwelling adults aged 60 years or over, opioid use wasAdjusted
lue HR 95% CI P value
rence 1.0 Reference Reference
01 1.46 1.20–1.78 <0.001
01 1.40 0.91–2.16 0.122
01 2.40 2.01–2.85 <0.001
01 1.72 1.43–2.07 <0.001
01 1.98 1.68–2.33 <0.001
rence 1.0 Reference Reference
01 2.68 2.14–3.36 <0.001
01 2.22 1.70–2.91 <0.001
01 1.96 1.70–2.26 <0.001
01 1.47 1.21–1.78 <0.001
01 1.92 1.63–2.26 <0.001
d ratio; CI: confidence interval. Adjusted for age, gender, comorbidity, previous
A. Taqi et al. Osteoarthritis and Cartilage Open 3 (2021) 100165associated with an increased risk of fall OR (95% CI) 2.4 (1.5, 3.7) [33].
Additionally, in a population based nested case control study, using data
from Scania’s 245 healthcare database, the risk of fall associated with
opioid use was reported separately for men and women as follows: OR
(95% CI) 1.92 (1.68, 2.20) and 1.90 (1.49, 2.24) respectively [34].The
present study showed a stronger association between current opioids use
and the risk of fall, earlier in the follow-up period compared to the later
6–12 months. This was also consistent with previous research. Soderberg
et al. (2013), in a population-based case-crossover study from Sweden,
identified the period of the first 28 days after opioid initiation as a
high-risk period for sustaining a fall-related injury, HR (95% CI) was 2.85
(2.74, 3.00) [35]. The risks were greater during the first week after the
start of treatment than during the three consecutive weeks and the re-
ported estimates were 5.14 (4.76, 5.55), 2.57 (2.35, 2.81) 1.46 (1.31,
1.62) and 1.23 (1.10, 1.38) for weeks 1–4 respectively [35]. It is possible
that the greatest risk related to opioid treatment is after initiation and is
due to sedation, dizziness and cognitive impairment, all of which are risk
factors for falls [36].
In a recent study using CPRD a higher risk of fall was reported during
episodes of long-term use of opioids: HR (95% CI) 1.23 (1.19, 1.28)
compared to non-long-term use [19]. These estimates were lower than
those from the present study for opioids in the first 6 months (HR 2.40
[95% CI 2.01, 2.85]), which may be explained by the fact that fall events
were captured after long-term use was established (i.e. after 90 days of
use) which meant that events which occurred after opioid initiation were
not included.
The association between the use of NSAIDs and paracetamol and the
risk of fall is less well studied compared to other analgesics. Moreover,
the available studies have analysed their exposure as a time-fixed vari-
able and therefore could not be compared to results from the present
study [37]. Our results are biologically plausible, as the blood-brain
barrier becomes more permeable with age letting easier passage of
medications. Opioids have psychotropic effects and can cause drowsiness
and dizziness [38], while for antidepressants and AEDs, possible under-
lying causes include sedation, insomnia and confusion [39]. Similarly,
NSAIDs can cross the blood-brain barrier and cause adverse CNS effects
[40], however, the exact mechanism by which paracetamol might put
people at risk of fall is unclear.
4.3. Strengths and limitations
This study was population based rather than hospital-based, its size
allowed the inclusion of sufficient numbers within each analgesic class,
hence, its findings are generalisable to all patients with KOA. The study
included several medicine classes, most of which are recommended by
clinical guidelines [4,5] and are commonly prescribed by GPs.
Analgesic use was treated as a time-varying exposure and related the
risk of fall to the analgesic drug class currently being used, rather than
basing the results on other analgesic use patterns such as after long-term
use [19]. The estimated risk of falls may vary with different definitions of
long-term use (e.g. 3 months after the first prescription or 3 prescriptions
within 90 days after first prescribing) and it implies missing events
occurring before the long-term use was established. The time-varying
analysis addressed a common and often overlooked source of bias in
epidemiological studies, namely the ITB [41]. This type of bias can
potentially overestimate the risk of the outcome, stemming from expo-
sure misclassification (i.e. patients were classified as exposed when they
are actually not).
The main limitations with the present study are indication and
ascertainment bias. Indication bias is found when medications are pre-
scribed for a condition that is itself associated with the outcome of in-
terest [42]. KOA pain itself is associated with the adverse outcome of
interest, fall; however, the TV analysis ensured that the same patient was
a user at a period and a non-user of analgesics at the subsequent period.
Additionally, there may be other confounders that were not adjusted
for, such as alcohol intake. Alcohol has long been considered as a risk5
factor for falls; however, a number of published studies have failed to
confirm this assumption [43]. Nevertheless, this may have overestimated
the risk of falls with analgesic use. It was assumed that that prescribed
medicines were dispensed and actually taken by patients. This may
overestimate exposure, as research has shown that up to 50% of patients
do not comply with long-term therapies [44].
Although the prescription records were comprehensive, OTC drug
utilisation is not recorded in the CPRD, which may have led to an un-
derestimation of drug exposure as paracetamol and some NSAIDs (e.g.
Ibuprofen 200 mg and 400 mg) are widely accessed as OTC products.
However, most of the included patients were aged over 60 years old, thus
qualifying for free prescriptions in the UK [45].
The diagnoses of KOA and fall were not validated in the present study;
however, the validity of diagnoses in CPRDwas examined in a systematic
review including 183 different diagnoses. It reported an overall high
estimate of validity as the median proportion of cases with a confirmed
diagnosis was 89% [22]. Moreover, the diagnosis of hip OA recording in
CPRD was validated in a study including a random sample of 170 cases,
where the positive predictive value of hip OA codes was found to be 79%
based on clinical criteria [46]. Data from UK primary care databases
(CPRD, QResearch and THIN) have been previously used to examine the
association between medication use and the risk of adverse events
including falls [16,17]. Prescription data in CPRD are reliably recorded;
however, analgesics received during hospitalisation episodes were not
included. As the majority of people with KOA are managed in primary
care, this should not have had much effect on the findings.
The model treated drug use as a time varying exposure, hence a
separate cox model was run for each analgesic class. Classifying the use
and non-use periods for a given analgesic, while taking into account the
status of use of the remaining four classes would generate a complex
model with potential instability. Therefore, analyses were not expanded
to consider multiple medications, however the model adjusted for the use
of other analgesics (other than the class being analysed). Finally, a
generalised ascertainment bias may have arisen as patients attending
primary care consultations are more likely to report falls, or recall them
when asked, than those not attending such consultations. Clinicians
treating patients who are prescribed medications may be more conscious
with regard to enquiring about falls in compliance with national guid-
ance [47]. On the other hand, patients are less likely to report or recall
falls where they did not experience an injury, hence leading to a potential
underestimation/under ascertainment of the outcome.
Several variables, which may potentially have influenced the risk of
falling are not captured in CPRD, such as pain intensity, severity of
comorbidities, and certain lifestyle measures (e.g. physical activity).
However, the studied patients probably had similar levels of pain severity
or physical function impairment, when labelled with a diagnosis of KOA
[48].
Findings from the present study suggest optimised fall-prevention
strategies during periods of medication use in patients with KOA.
Firstly, risk of falls should be highlighted with starting and monitored
during treatment. Prescribers as well as patients need to be aware of such
information and follow appropriate measures, such as restricting (if
appropriate) new prescriptions of any additional treatments which may
increase the risk of falls. Keeping patients and practitioners informed
(through offering oral and written information) of the heightened risk of
fall during periods of medication use will optimise self-care, an important
component of fall prevention programs. Taken together, these results
convey a clear message on the need to prioritise patients with KOA taking
analgesics for falls risk assessment, management and prevention strate-
gies, in order to achieve optimal care and safety of prescribed analgesics
within this group of patients.
The striking finding is that current paracetamol use was associated
with an increased risk of falling among the studied patients, which forms
an additional call for routine reviews to ensure the safety of patients who
are prescribed any analgesic, even those regarded as safe (e.g. paracet-
amol). It is still possible that the results for paracetamol were driven by
A. Taqi et al. Osteoarthritis and Cartilage Open 3 (2021) 100165the fact that users were older patients, who in general are more likely to
fall and have serious falls, however, age was adjusted for in the analysis.
The study also identifies community dwelling people with KOA
currently using analgesics as a high-risk group for falls which implies
regarding them as a group with a priority for referral to fall clinics. Future
work needs to examine the association between current exposure to
higher compare to lower dosage ranges to explore any dose-response
relationship between analgesics’ use and falls. It will also be worth
exploring the risk in a sample of KOA with and without comorbidities
separately.
5. Conclusion
This study quantified the risk associated with the current use of an-
algesics within one year of KOA diagnosis. The association varied be-
tween the two 6-month intervals of the year; opioids, NSAIDs and
paracetamol showed a stronger association within the first 6-month in-
terval, while antidepressants and AEDs showed a stronger association
within the second 6-month interval. These findings add to the body of
knowledge on safety of analgesic medicines in people with KOA.
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